Evidence map›Paper›PMID 22033920›Full record

ArticleThe Journal of biological chemistry2011

Mitogen-activated protein kinase extracellular signal-regulated kinase 2 phosphorylates and promotes Pin1 protein-dependent promyelocytic leukemia protein turnover.

Jun Hee Lim, Yu Liu, Erin Reineke, Hung-Ying Kao

Open access · hybridAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Differential Roles of PML Isoforms.Frontiers in oncology · 2013
    Article
  20. Is PML a Tumor Suppressor?Frontiers in oncology · 2013
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jun Hee LimDepartment of Biochemistry, School of Medicine, Case Western Reserve University, Cleveland, Ohio 44106-4935, USA.
Yu Liu
Erin Reineke
Hung-Ying Kao
Case Western Reserve University · US

Funding

Alpha actinin 4: its functions and regulationR01DK078965 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI KAO, HUNG-YING · 2009 to 2013
$1.7M
Histone deacetylase 7 and its interacting proteins in endothelial cellsR01HL093269 · NHLBI · CASE WESTERN RESERVE UNIVERSITY · PI KAO, HUNG-YING · 2010 to 2013
$1.5M
NHLBI NIH HHS HL093269NHLBI NIH HHS R01 HL093269NIDDK NIH HHS R01 DK078965
6 · The paper itself

Abstract

The promyelocytic leukemia (PML) protein is a tumor suppressor that has an important role in several cellular processes, including apoptosis, viral infection, DNA damage repair, cell cycle regulation, and senescence. PML is an essential component of sub-nuclear structures called PML nuclear bodies (NBs). Our laboratory has previously demonstrated that the peptidyl-prolyl cis-trans isomerase, Pin1, binds and targets PML for degradation in a phosphorylation-dependent manner. To further elucidate the mechanisms underlying Pin1-mediated PML degradation, we aimed to identify one or more factors that promote PML phosphorylation. Here we show that treatment with U0126, an inhibitor of the ERK2 upstream kinases MEK1/2, leads to an increase in PML protein accumulation and an inhibition of the interaction between Pin1 and PML in MDA-MB-231 breast cancer cells. Consistent with this observation, phosphorylated ERK2 partially co-localized with PML NBs. Although U0126 up-regulated exogenous wild-type PML levels, it did not have an effect on the steady-state level of a mutant form of PML that is defective in binding Pin1. In addition, exogenous wild-type, but not Pin1 binding-defective PML protein expression levels were decreased by overexpression of ERK2. In contrast, knockdown of ERK2 by siRNA resulted in an increase in PML protein levels and an increase in the formation of PML NBs. Using phospho-specific antibodies, we identified Ser-403 and Ser-505 as the ERK2 targets that promote Pin1-mediated PML degradation. Finally, we demonstrated that EGF induced activation of ERK and interaction between PML and phosphorylated ERK resulting in a decrease in PML protein levels. Taken together, our results support a model in which Pin1 promotes PML degradation in an ERK2-dependent manner.

Indexed as

Models, BiologicalProteolysisAnimalsButadienesEnzyme InhibitorsHEK293 CellsHeLa CellsHumansMAP Kinase Kinase 1MAP Kinase Kinase 2MiceMice, KnockoutMitogen-Activated Protein Kinase 1NIMA-Interacting Peptidylprolyl IsomeraseNitrilesNuclear ProteinsButadienesEnzyme InhibitorsMAP2K1 protein, humanMap2k1 protein, mouseMAP2K2 protein, humanMap2k2 protein, mouseMAPK1 protein, humanMAP Kinase Kinase 1MAP Kinase Kinase 2Mitogen-Activated Protein Kinase 1NIMA-Interacting Peptidylprolyl IsomeraseNitrilesNuclear ProteinsPeptidylprolyl IsomerasePIN1 protein, humanPin1 protein, mousePML protein, humanPml protein, mousePromyelocytic Leukemia ProteinTranscription FactorsTumor Suppressor ProteinsU 0126

Identifiers

PMID22033920
PMCPMC3248013
OpenAlexW2157522406

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.